london euretina

This meeting has been awarded 20 CME credits

Security Notice

Please note that Kuoni are our only destination management company. Other venders indicating that are operating for the society should be ignored. We never use western union as a payment portal

Posters

Clinical follow-up of statins` use in complex treatment of exudative form of age-related macular degeneration

Poster Details

First Author: M.Karliychuk UKRAINE

Co Author(s):    S. Pinchuk   M. Zubovych               0   0 0   0 0   0 0   0 0

Abstract Details



Purpose:

To assess the dynamics of retinal morphologic and functional changes in patients with exudative form of age-related macular degeneration after intravitreal injection of ranibizumab and statins` therapy.

Setting:

Department of Ophthalmology of Bukovinian State Medical University, Eye microsurgery clinic “Vash Zir”, Chernivtsi, Ukraine

Methods:

The study comprised 22 patients (24 eyes) with a mean age of 62,4 years with exudative form of age-related macular degeneration (AMD) after 3 consecutive monthly intravitreal injections of ranibizumab (Lucentis®). The drug was injected through the pars plana 3,5 mm posterior to the limbus using a 30-gauge needle. 12 patients (13 eyes) of main group received statins` therapy in dose 10 mg per day during 6 months. The major efficacy criteria were the corrected visual acuity (VA) changes from baseline, morphological changes in macula (central macular thickness, CMT) according to optical coherence tomography (OCT) (RTVue-100, Optovue, USA) data (3D-macula Protocol, Macula Thickness Map Program) and the number of reinjection required over the 12-month follow-up. Statistical significance was defined as р<0,05. Retreatment was recommended if new or persistent fluid was demonstrated on OCT; an increase in CMT from previous measurement due to fluid on OCT; VA deterioration related to fluid on OCT.

Results:

At baseline, the mean VA was 0,16±0,14; a mean CMT at baseline was 379,34±103,61 μm. At 6 months after the first ranibizumab injection the best corrected VA was remarkably higher (0,48±0,20) as compared with its baseline value (р<0,05) in all patients. At 12 months VA in patients of main group was 0,41±0,19, in patients of control group - 0,32±0,16 without statistically significant difference. CMT values at 6 months were 314,46±62,34 μm in main group and 322,44±64,67 μm in control group; at 12 months - 284,32±64,67 μm and 318,30±67,56 μm, respectively (р<0,05). During 12-month follow-up 23,08% eyes of main group and 45,46% eyes of control group needed retreatment.

Conclusions:

It was established that statins` administration in complex treatment of exudative form of AMD helps to preserve the effect of anti-VEGF therapy and reduce the number of reinjection that allows to recommend them for use in this pathology.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy